{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-010990","form_type":"8-K","ticker":null,"cik":"0001325879","company_name":"AVEO PHARMACEUTICALS, INC.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.415498+00:00","generated_at":"2026-06-20T12:57:43.497732+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"AVEO Pharmaceuticals acquired by LG Chem for $15 per share in all-cash deal; stock to be delisted","bullets":["Total aggregate consideration of ~$570.6M for shares and stock option settlement.","Loan agreement terminated; $3.18M in prepayment and end-of-term charges paid.","AVEO shares will be suspended from Nasdaq and deregistered with SEC.","Board resigned; Jaywin Lee becomes sole director; new CFO named on interim basis.","AVEO continues operations under AVEO Oncology name, led by existing CEO Michael Bailey."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-010990","json":"https://secwatch.observer/filing/0001193125-23-010990.json","markdown":"https://secwatch.observer/filing/0001193125-23-010990.md","text":"https://secwatch.observer/filing/0001193125-23-010990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/d450299d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:57:43.497732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16492a9799","claim":"Jaywin Lee was appointed as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"Jaywin Lee became the sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1d0e674d63","claim":"Erick Lucera was appointed as Chief Financial Officer at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"Mr. Lucera will serve as the Company’s Chief Financial Officer during a temporary transition period","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1de6191fca","claim":"Kevin Cullen resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1ef57a0557","claim":"Gregory Mayes resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"294938a363","claim":"Jebediah Ledell was appointed as Executive Officer at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Michael Bailey, Michael Ferraresso, Jebediah Ledell and Erick Lucera was appointed as an executive officer of the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6b18ec6011","claim":"Anthony Evnin resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"72e5e9528b","claim":"Scarlett Spring resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"84cd61e9e6","claim":"Kenneth Bate resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c00c3df193","claim":"Michael Bailey resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e7e9f9b8af","claim":"Michael Ferraresso was appointed as Executive Officer at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Michael Bailey, Michael Ferraresso, Jebediah Ledell and Erick Lucera was appointed as an executive officer of the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f59a6bf4f6","claim":"Corinne Epperly resigned as Director at AVEO PHARMACEUTICALS, INC..","evidence_excerpt":"each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0cdf52afe85222ee574ddca9d7a01cb81c9a3bf1","claim":"AVEO PHARMACEUTICALS, INC.: Amended and restated certificate of incorporation in its entirety.","evidence_excerpt":"Pursuant to the Merger Agreement, as of the Effective Time, the restated certificate of incorporation of the Company, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"b93ff790375a083a83fd041f64eb99ddf1ca8711","claim":"AVEO PHARMACEUTICALS, INC.: Amended and restated second amended and restated bylaws in their entirety.","evidence_excerpt":"In addition, as of the Effective Time, in accordance with the Merger Agreement, the second amended and restated bylaws of the Company, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (the “Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"26623a293976075e8c061b7f9da6dbcc170c3778","claim":"AVEO PHARMACEUTICALS, INC. underwent a change of control involving LG Chem, Ltd. for $15.00 per Share in cash (closed 2023-01-19).","evidence_excerpt":"(“Merger Sub”), a Delaware corporation and an indirect wholly owned subsidiary of LG Chem, Ltd., a corporation organized and existing under the laws of the Republic of Korea (“LG Chem”), whereby Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and an indirect wholly owned subsidiary of LG Chem (the “Merger”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"LG Chem, Ltd."},{"label":"Consideration","value":"$15.00 per Share in cash"},{"label":"Closing","value":"2023-01-19"}],"fact_type":"ma_transaction"},{"claim_id":"f0f6162013560159d97987f8c9d749bc2d6d7fc3","claim":"AVEO PHARMACEUTICALS, INC. terminated Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. as administrative agent and collateral agent for itself and a lender valued at $3,180,000 (effective 2023-01-19).","evidence_excerpt":"On January 19, 2023, in connection with the completion of the Merger (as defined below), AVEO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), prepaid in full all amounts owing and terminated all lending commitments under the Amended and Restated Loan and Security Agreement, dated as of December 28, 2017","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc. as administrative agent and collateral agent for itself and a lender"},{"label":"Value","value":"$3,180,000"},{"label":"Effective","value":"2023-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}